Ethinamate

Summary

Ethinamate (CHEMBL1576) is an approved small-molecule sedative.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 167.2 Da · C9H13NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1576
Name	Ethinamate
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3284
ChEBI	CHEBI:4884
Molecular formula	C9H13NO2
Molecular weight	167.2
InChIKey	GXRZIMHKGDIBEW-UHFFFAOYSA-N

SMILES: C#CC1(CCCCC1)OC(=O)N

IUPAC name: (1-ethynylcyclohexyl) carbamate

ChEBI definition: A carbamate ester that is the 1-vinylcyclohexyl ester of carbamic acid. A short-acting sedative-hypnotic, it was formerly used to treat insomnia.

Pharmacological roles (ChEBI): sedative.

Also known as: Ethinamate, Etinamato, NSC-11538, Valmid, ETHINAMATE, ethinamate

Patent coverage: 585 distinct patent families (2,154 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).